The following full text is a publisher’s version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/138086

Please be advised that this information was generated on 2019-08-30 and may be subject to change.
Genetic comorbidities in Parkinson’s disease

Mike A. Nalls1,*, Mohamad Saad2,3, Alastair J. Noyce4, Margaux F. Keller1,6, Anette Schrag6, Jonathan P. Bestwick7, Bryan J. Traynor1, J. Raphael Gibbs1,11, Dena G. Hernandez1,11, Mark R. Cookson1, Huw R. Morris5,8, Nigel Williams8, Thomas Gasser9,10, Peter Heutink10, Nick Wood11,12, John Hardy11, Maria Martinez2,3, and Andrew B. Singleton1 for the International Parkinson’s Disease Genomics Consortium (IPDGC), The Wellcome Trust Case Control Consortium 2 (WTCCC2), North American Brain Expression Consortium (NABEC) and the United Kingdom Brain Expression Consortium (UKBEC)

1Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA 2Institut National de la Sante et de la Recherche Medicale, UMR 1043, Centre de Physiopathologie de Toulouse-Purpan, Toulouse, France 3Paul Sabatier University, Toulouse, France 4Reta Lila Weston Institute of Neurological Studies, 5Department of Clinical Neuroscience, UCL Institute of Neurology, London, UK 6Department of Biological Anthropology, Temple University, Philadelphia, PA, USA 7Wolfson Institute for Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK 8Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Cardiff University School of Medicine, Cardiff, UK 9Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tubingen, Tubingen, Germany 10DZNE-Deutsches Zentrum für Neurodegenerative Erkrankungen (German Center for Neurodegenerative Diseases), Tubingen, Germany 11Department of Molecular Neuroscience, Institute of Neurology and 12UCL Genetics Institute, University College London, London, UK

Received June 4, 2013; Revised September 10, 2013; Accepted September 17, 2013

Parkinson’s disease (PD) has a number of known genetic risk factors. Clinical and epidemiological studies have suggested the existence of intermediate factors that may be associated with additional risk of PD. We construct genetic risk profiles for additional epidemiological and clinical factors using known genome-wide association studies (GWAS) loci related to these specific phenotypes to estimate genetic comorbidity in a systematic review. We identify genetic risk profiles based on GWAS variants associated with schizophrenia and Crohn’s disease as significantly associated with risk of PD. Conditional analyses adjusting for SNPs near loci associated with PD and schizophrenia or PD and Crohn’s disease suggest that spatially overlapping loci associated with schizophrenia and PD account for most of the shared comorbidity, while variation outside of known proximal loci shared by PD and Crohn’s disease accounts for their shared genetic comorbidity. We examine brain methylation and expression signatures proximal to schizophrenia and Crohn’s disease loci to infer functional changes in the brain associated with the variants contributing to genetic comorbidity. We compare our results with a systematic review of epidemiological literature, while the findings are dissimilar to a degree; marginal genetic associations corroborate the directionality of associations across genetic and epidemiological data. We show a strong genetically defined level of comorbidity between PD and Crohn’s disease as well as between PD and schizophrenia, with likely functional consequences of associated variants occurring in brain.
INTRODUCTION

Parkinson’s disease (PD) is recognized to be associated with a number of genetic susceptibility factors, including variability at the loci SNCA, LRRK2, MAPT, BST1, GAK, HLA-DR, ACM5D, STK39, MCCCI/LAMP3, SFT11, CCDC62/HIP1R, PARK16/1q32, STX1B/16p11, GFG20/8p22, STBD1/4q21, GPNMB/7p15, among others, which have been identified in genome-wide association studies (GWAS). It is likely that other additional genetic risk factors also contribute. PD has been reported to be associated with a number of clinical comorbidities and altered laboratory values, such as affective disorders and serum urate levels. Several of these have themselves been associated with genetic susceptibility factors, for which information is available from the NHGRI GWAS catalog (http://www.genome.gov/26525384, (1)).

This offers the opportunity to examine genetic risk profiles associated with these clinical phenotypes as risk factors for PD. Genetic risk profiles may be thought of as the cumulative genetic load of risk alleles related to a particular disease or trait, explaining more of the attributable genetic risk associated with this disorder than a single SNP itself. While many epidemiological studies examine associations between intermediate phenotypes and a specific outcome, in this study we sought to examine how the genetic risk profiles associated with these intermediate phenotypes may be associated with PD risk themselves. We sought to identify genetic comorbidities of PD by testing associations with genetic risk profiles previously associated with intermediate phenotypes of interest. Any disease or trait with a significant risk profile score associated with PD essentially would share some genetic factors in common.

In this study, we identify PD genetic comorbidities such as Crohn’s disease and schizophrenia. We also attempt to dissect the individual contributions of these associated loci in their contributions to PD risk. Additionally, we utilize expression and methylation data to infer functional genetic consequences in brain tissues associated with these genetic comorbidities.

RESULTS

We used a large sample series of >5000 PD cases and 9000 controls with genome-wide genotyping data (Table 1). We defined a list of clinical factors that are potentially associated with PD risk or comorbidity. We then examined how SNPs associated with these clinical factors might be associated with PD itself using a measure of the cumulative effect of all SNPs related to that particular factor (Supplementary Material, Tables S1 and S2). We identified 18 clinical factors suggested by the literature and clinical observation to be possible factors associated with PD for which there were high-quality GWAS results in the NHGRI catalog (http://www.genome.gov/26525384, (1)). These include: serum amyloid, bipolar disorder, caffeine intake, Crohn’s disease, hypertension, inflammation, serum iron, melanoma, obesity, PD, psoriasis, rheumatoid arthritis, schizophrenia, smoking, type 2 diabetes, ulcerative colitis and serum urate (2–68). As a note, PD was included as a positive control. For these phenotypes of interest, alleles associated with an increase in risk for binary phenotypes and/or alleles associated with increase in the level of continuous phenotypes were summed to create the genetic risk profiles.

Within each of the five IPDGC cohorts participating in this analysis, each risk profile comprising a number of SNPs was tested using logistic regression for an association with PD status, adjusting for sex, age at onset/exam and population substructure. Summary statistics from each cohort were combined through meta-analysis under random effects to account for possible heterogeneity (see Figure1 and Table 2). This resulted in three genetic risk profiles being significantly associated with PD. These include profiles based on SNPs taken from studies of Crohn’s disease, schizophrenia and PD. A single standard deviation increase in the genetic risk profile for PD, equivalent to roughly a 34% increase in the genetic burden associated with known PD risk alleles within a population, was associated with an odds ratio (OR) of 1.29 (95% confidence interval 1.22–1.38, P-value <2E–16). Using the same burden scale, a single standard deviation increase from population means in the allelic burdens derived from Crohn’s disease and schizophrenia risk profiles was significantly associated with PD status at an OR of 1.06 (95% confidence interval 1.02–1.11, P-value 0.005) and 1.05 (95% confidence interval 1.01–1.10, P-value 0.012), respectively.

All 96 SNPs within these three risk profiles (Crohn’s disease, PD and schizophrenia) were tested independently for association with PD using identical statistical models and meta-analytic methods as described for the analyses of risk profiles (Supplementary Material, Table S3). Two SNPs not previously known to be associated with PD passed Bonferroni correction for 99 tests. The first was rs11191580, a SNP in the NT5C2 gene known to be associated with schizophrenia. This SNP reached genome-wide significance in our testing (risk associated with reference allele T at OR 1.35, 95% confidence interval 1.21–1.50, P-value 3.98E–8, T frequency 91.2%). The region surrounding rs11191580 was suggested to be associated with PD.

Table 1. Descriptive statistics of cohorts contributing to analyses

<table>
<thead>
<tr>
<th>Cohort</th>
<th>Cases</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Age at onset, mean (SD) in years</td>
<td>% Female</td>
</tr>
<tr>
<td>France</td>
<td>57.548 (13.086)</td>
<td>41.523</td>
</tr>
<tr>
<td>Germany</td>
<td>55.715 (11.549)</td>
<td>39.595</td>
</tr>
<tr>
<td>Netherlands</td>
<td>55.649 (11.826)</td>
<td>36.446</td>
</tr>
<tr>
<td>NIA—USA</td>
<td>57.812 (13.156)</td>
<td>40.235</td>
</tr>
<tr>
<td>UK</td>
<td>64.167 (12.434)</td>
<td>42.051</td>
</tr>
</tbody>
</table>

NIA denotes cohorts with data generated at the Laboratory of Neurogenetics at the National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
initially in a previous publication by Simon-Sanchez et al. using a portion of the IPDGC data (42). However, the association at this locus was never definitively replicated in a European ancestry population and was therefore not included in the PD genetic risk profiles we have constructed in this report (42). The other SNP passing Bonferroni correction was rs11564258, a SNP near the LRRK2 risk locus from the Crohn’s disease risk profile, at an OR of 0.69 associated with the G reference allele (95% confidence interval 0.58–0.83, P-value 5.49E–5, G frequency 97.5%) showing possible LD with the LRRK2 PD risk locus (49).

To assess the independence of the risk profile associations outside of possible spatial overlaps with PD loci, risk profile score associations were recalculated adjusting for SNPs near PD risk loci as covariates. Keller et al.’s summary of PD loci was used, in addition to data mined from the GWAS catalog to further scrutinize putative PD loci (69). To define SNPs used as covariates, they must be within 1 mb of a PD risk locus described in either the downloaded GWAS catalog, Keller et al. or Simon-Sanchez et al. (1,42,69). When adjusting for SNPs near PD risk loci as covariates, the schizophrenia risk profile association was reevaluated adjusting for rs11191580 and rs7914558 in NT5C2 and rs3131296 near the HLA-DRA risk locus as additional covariates. The Crohn’s disease risk profile association was adjusted for rs11564258 and rs11175593 near LRRK2, rs17309827 near HLA-DRA and rs1736135 near the suspected PD risk locus at USP25. After meta-analyzing the cohort-specific summary statistics adjusted for these SNPs, the association between the Crohn’s disease’s risk profile remained significantly associated with PD risk (OR 1.05, 95% confidence interval 1.01–1.09, P-value 0.03), while the schizophrenia association was completely attenuated (OR 0.99, 95% confidence interval 0.92–1.06, P-value 0.76). This suggests that there are additional genetic factors outside of known PD loci overlap that contribute to the genetic comorbidity shared by PD and Crohn’s disease, while the genetic comorbidity shared by schizophrenia and PD may simply be due to possible overlapping loci, although the association at NT5C2 in PD remains to be definitively replicated.

Systematic review data were extracted for overlapping phenotypes from Noyce et al. (1) to evaluate how genetic risk may be
reflected in epidemiological data (Table 3). Neither Crohn’s disease or schizophrenia associations were significantly replicated in the epidemiological data, although the directionality of effect for psychosis aspects of schizophrenia and Crohn’s disease mirror genetic risk estimates associated with PD. The directionality of effect in our study of genetic factors relating to PD comorbidity leads support to the effects described in the statistically significant epidemiologically evaluated comorbidities of smoking status, coffee drinking and hypertension as described in the systematic review.

Mining of brain tissue to infer possible biological functionality at loci associated with PD, Crohn’s disease and schizophrenia, we examined regional methylation and expression data within ± 1 mb of SNPs of interest in a large series of neurologically normal frontal cortex and cerebellar tissues. While we identified a number of loci significantly associated with methylation and expression changes in the brain tissue samples, our primary interest was to focus on SNPs from overlapping regions identified as risk loci for PD and Crohn’s or PD and schizophrenia (Table 4). SNPs in the HLA region used to construct the Parkinson’s and schizophrenia profiles were significantly associated with changes in regional methylation status in both the frontal and cerebellar tissue samples, allowing us to infer functional consequence in brain tissues associated with these proximal risk SNPs. Alleles at this locus associated with risk of PD and schizophrenia were concurrently associated with decreased methylation in the frontal cortex (49). We also show that a Crohn’s disease-associated SNP near the LRRK2 PD risk locus is also significantly associated with methylation changes in the frontal cortex. This suggests that genetic variants associated with Crohn’s disease and schizophrenia (in addition to PD) may alter brain function to some degree.

### DISCUSSION

In this study, we identified Crohn’s disease and schizophrenia as genetic comorbidities of PD. The genetic risk profiles based on GWAS identified loci for these two diseases showed significant risk associated with PD. The genetic comorbidity associated with schizophrenia was almost entirely accounted for by SNPs in the PD associated loci near NT5C2 and HLA-DRA. On the other hand, Crohn’s disease’s risk profile and PD remained significantly associated even when adjusting for overlapping SNPs at loci near known PD risk loci USP25, HLA-DRA and LRRK2. This suggests that additional risk loci associated with Crohn’s disease are also connected to PD risk, outside of those already near known PD loci. In the near future, deep sequencing of large population based studies should help clarify further genetic comorbidities and provide greater insight into the mechanisms of multiple related diseases.

There seems to be functional connectivity between these diseases based on our analyses of expression and methylation data. SNPs associated with both schizophrenia and Crohn’s disease cause significant changes in proximal methylation and expression levels in the brain, allowing for the inference of functional changes occurring in the brain related to these genetic comorbidities. The associated changes in methylation and expression status surrounding these SNPs mirrors their genomic context in previous analyses related to PD (49,70). Future studies with single cell capture designs, deep sequencing and additional brain tissue regions sampled may better quantify possible functional genetic consequences in PD etiology.
study and in other GWAS of both schizophrenia and PD. There is a long history of drug-induced parkinsonism that is often acute in onset (76), and misdiagnosis could affect the power and validity of our current study. However, as part of the Queen Square Brain Bank diagnostic criteria utilized to diagnose a majority of samples contributed to the IPDGC consortium effort, we believe that the possible effect of drug-induced PD is minimal, as a concurrent diagnosis of schizophrenia was an exclusionary criteria that the possible effect of drug-induced PD is minimal, as a consequence of this study has successfully identified comorbid intermediate factors associated with PD, as this study has >95% power to detect an effect at the magnitude of the schizophrenia and Crohn’s disease.

### Table 3. Systematic review of epidemiological literature for select traits of interest

<table>
<thead>
<tr>
<th>Factor</th>
<th>Study/studies (n)</th>
<th>Cases (n)</th>
<th>Controls (n)</th>
<th>OR</th>
<th>Lower limit of the OR 95% confidence interval</th>
<th>Upper limit of the OR 95% confidence interval</th>
<th>SE</th>
<th>P-value</th>
<th>I²</th>
<th>Heterogeneity P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ever versus never smoking&lt;sup&gt;a&lt;/sup&gt;</td>
<td>67</td>
<td>19 518</td>
<td>1 053 664</td>
<td>0.64</td>
<td>0.6</td>
<td>0.69</td>
<td>0.0347</td>
<td>&lt;0.001</td>
<td>49.60%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Drinking versus non-drinking coffee&lt;sup&gt;b&lt;/sup&gt;</td>
<td>19</td>
<td>5 801</td>
<td>723 072</td>
<td>0.67</td>
<td>0.58</td>
<td>0.76</td>
<td>0.0654</td>
<td>&lt;0.001</td>
<td>42.90%</td>
<td>0.025</td>
</tr>
<tr>
<td>Hypertension preceding PD&lt;sup&gt;c&lt;/sup&gt;</td>
<td>12</td>
<td>5 993</td>
<td>187 226</td>
<td>0.74</td>
<td>0.61</td>
<td>0.9</td>
<td>0.0989</td>
<td>0.003</td>
<td>76.50%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Diabetes preceding PD&lt;sup&gt;d&lt;/sup&gt;</td>
<td>13</td>
<td>20 025</td>
<td>303 543</td>
<td>0.91</td>
<td>0.72</td>
<td>1.15</td>
<td>0.1189</td>
<td>0.423</td>
<td>70.90%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Melanoma preceding PD&lt;sup&gt;e&lt;/sup&gt;</td>
<td>6</td>
<td>–</td>
<td>–</td>
<td>1.07</td>
<td>0.62</td>
<td>1.84</td>
<td>–</td>
<td>–</td>
<td>49.30%</td>
<td>0.079</td>
</tr>
<tr>
<td>Serum iron&lt;sup&gt;f&lt;/sup&gt;</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>BiPolar disorder preceding PD</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Psoriasis preceding PD</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Ulcerative colitis preceding PD</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Crohn’s disease preceding PD</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Rheumatoid arthritis preceding PD</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Blood inflammatory markers preceding PD&lt;sup&gt;g&lt;/sup&gt;</td>
<td>84</td>
<td>16 5</td>
<td>3 4</td>
<td>3.4</td>
<td>1.1</td>
<td>10.5</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Obesity preceding PD&lt;sup&gt;h&lt;/sup&gt;</td>
<td>3/7 studies described significant associations with obesity preceding PD through a variety of different measures (RR/OR 2.8&lt;sup&gt;i&lt;/sup&gt;, 2.03&lt;sup&gt;i&lt;/sup&gt;, 0.43&lt;sup&gt;i&lt;/sup&gt;, 0.9, 0.8, 0.86, 0.99)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Urate level preceding PD&lt;sup&gt;i&lt;/sup&gt;</td>
<td>3/5 studies described significant associations with elevated urate preceding PD using various cut-offs (ORs 0.4&lt;sup&gt;j&lt;/sup&gt;, 0.6&lt;sup&gt;j&lt;/sup&gt;, 0.71&lt;sup&gt;j&lt;/sup&gt;, 0.43, 1.33) and 1 with preceding gout (OR 0.69&lt;sup&gt;j&lt;/sup&gt;)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Schizophrenia preceding PD&lt;sup&gt;j&lt;/sup&gt;</td>
<td>Two studies (Shiba et al., 71, 83); schizophrenia OR 1.0 (CI 0.1–7.0); Rajput et al., 74, 86; psychosis RR 1.5 (CI 0.3–6.7))</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Serum amyloid</td>
<td>No known epidemiological studies comparing serum amyloid levels between PD and controls</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

NS, non-significant but figures not provided; NA, not available; RR, relative risk.

<sup>a</sup>Summary data from meta-analysis undertaken by Noyce et al. (1).
<sup>b</sup>Summary data from meta-analysis undertaken by Liu et al. (86). NB: After exclusion of the only negative study OR 1.44 (CI 1.06–1.96); association of existing PD with melanoma OR 3.61 (CI 1.49–8.77).
<sup>c</sup>Summary data from meta-analysis undertaken by Mariani et al. (87); data are for patients with established PD; Mariani et al. also report reduced transferrin and transferrin saturation.

<sup>d</sup>OR refers to highest quintile of IL-6 compared with the lowest (P for trend 0.03). Associations with high-sensitivity c-reactive protein (CRP), fibrinogen and tumor necrosis factor were non-significant. NB: In established PD, Song et al. (75, 87) reported increased high-sensitivity CRP compared with controls OR 2.04 (CI 1.18–3.52).

<sup>e</sup>Risk of bias through drug-induced parkinsonism due to neuroleptic treatment.

<sup>f</sup>Statistically significant result (where confidence interval not given).
Local changes in mRNA expression and CpG methylation are associated with SNPs of interest for Crohn’s disease, PD and schizophrenia

<table>
<thead>
<tr>
<th>SNP name</th>
<th>Chromosome</th>
<th>SNP position (bp, build 37)</th>
<th>Major allele, minor allele</th>
<th>MAF</th>
<th>Imputation quality (RQ from MinimMach)</th>
<th>Effect, based on minor allele dosage</th>
<th>Standard error</th>
<th>P-value</th>
<th>CpG or mRNA probe</th>
<th>Assay</th>
<th>Tissue sampled</th>
<th>Distance from SNP to probe (bp)</th>
<th>Probe-associated gene</th>
<th>Phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs2274910</td>
<td>1</td>
<td>160852046</td>
<td>C.T</td>
<td>0.2776</td>
<td>1</td>
<td>--0.744</td>
<td>0.09</td>
<td>1.03E-16</td>
<td>cg10103688</td>
<td>CpG methylation</td>
<td>CRBLM</td>
<td>19384</td>
<td>CD244</td>
<td>Crohns</td>
</tr>
<tr>
<td>rs10181042</td>
<td>2</td>
<td>61224259</td>
<td>C.T</td>
<td>0.4224</td>
<td>0.9946</td>
<td>0.414</td>
<td>0.074</td>
<td>1.82E-08</td>
<td>ILMN_1754501</td>
<td>mRNA expression</td>
<td>FCTX</td>
<td>166006</td>
<td>NA</td>
<td>Crohns</td>
</tr>
<tr>
<td>rs9858542</td>
<td>3</td>
<td>49791983</td>
<td>G.A</td>
<td>0.3273</td>
<td>0.8285</td>
<td>0.485</td>
<td>0.095</td>
<td>3.05E-07</td>
<td>cg12788313</td>
<td>CpG methylation</td>
<td>CRBLM</td>
<td>24144</td>
<td>MST1</td>
<td>Crohns</td>
</tr>
<tr>
<td>rs2188962</td>
<td>5</td>
<td>131778085</td>
<td>C.T</td>
<td>0.4244</td>
<td>1</td>
<td>0.388</td>
<td>0.087</td>
<td>8.62E-06</td>
<td>cg20512303</td>
<td>CpG methylation</td>
<td>CRBLM</td>
<td>178796</td>
<td>PDMLM4</td>
<td>Crohns</td>
</tr>
<tr>
<td>rs2188965</td>
<td>5</td>
<td>131778085</td>
<td>C.T</td>
<td>0.4244</td>
<td>1</td>
<td>--0.388</td>
<td>0.087</td>
<td>8.76E-06</td>
<td>cg22598563</td>
<td>CpG methylation</td>
<td>CRBLM</td>
<td>206884</td>
<td>P4HA2</td>
<td>Crohns</td>
</tr>
<tr>
<td>rs359457</td>
<td>5</td>
<td>173279842</td>
<td>T.C</td>
<td>0.4171</td>
<td>0.999</td>
<td>0.463</td>
<td>0.074</td>
<td>4.26E-10</td>
<td>ILMN_1722025</td>
<td>mRNA expression</td>
<td>FCTX</td>
<td>105114</td>
<td>CPEB4</td>
<td>Crohns</td>
</tr>
<tr>
<td>rs359457</td>
<td>5</td>
<td>173279842</td>
<td>T.C</td>
<td>0.4171</td>
<td>0.999</td>
<td>0.672</td>
<td>0.075</td>
<td>2.31E-19</td>
<td>ILMN_1722025</td>
<td>mRNA expression</td>
<td>FCTX</td>
<td>105114</td>
<td>CPEB4</td>
<td>Crohns</td>
</tr>
<tr>
<td>rs13194053</td>
<td>6</td>
<td>27143883</td>
<td>T.C</td>
<td>0.1683</td>
<td>0.9872</td>
<td>0.516</td>
<td>0.109</td>
<td>2.26E-06</td>
<td>cg14345882</td>
<td>CpG methylation</td>
<td>FCTX</td>
<td>779090</td>
<td>BTN3A2</td>
<td>Schizophrenia</td>
</tr>
<tr>
<td>rs2021772</td>
<td>6</td>
<td>30174131</td>
<td>C.T</td>
<td>0.2031</td>
<td>0.9775</td>
<td>0.429</td>
<td>0.107</td>
<td>5.96E-05</td>
<td>cg17475918</td>
<td>CpG methylation</td>
<td>CRBLM</td>
<td>283056</td>
<td>HLA-E</td>
<td>Schizophrenia</td>
</tr>
<tr>
<td>rs3131296</td>
<td>6</td>
<td>32172993</td>
<td>C.T</td>
<td>0.4019</td>
<td>0.9875</td>
<td>--0.597</td>
<td>0.126</td>
<td>2.13E-06</td>
<td>cg25764570</td>
<td>CpG methylation</td>
<td>FCTX</td>
<td>234246</td>
<td>HLA-DRA</td>
<td>Schizophrenia</td>
</tr>
<tr>
<td>rs2395163</td>
<td>6</td>
<td>32387809</td>
<td>T.C</td>
<td>0.2251</td>
<td>1</td>
<td>0.42</td>
<td>0.102</td>
<td>3.46E-05</td>
<td>cg07363687</td>
<td>CpG methylation</td>
<td>FCTX</td>
<td>540863</td>
<td>SLC4A4</td>
<td>Parkinson</td>
</tr>
<tr>
<td>rs2395163</td>
<td>6</td>
<td>32387809</td>
<td>T.C</td>
<td>0.2251</td>
<td>1</td>
<td>0.42</td>
<td>0.102</td>
<td>3.46E-05</td>
<td>cg24156504</td>
<td>CpG methylation</td>
<td>FCTX</td>
<td>493976</td>
<td>C4B</td>
<td>Parkinson</td>
</tr>
<tr>
<td>rs3129882</td>
<td>6</td>
<td>32409530</td>
<td>A.G</td>
<td>0.4151</td>
<td>1</td>
<td>0.473</td>
<td>0.089</td>
<td>1.00E-07</td>
<td>cg25764570</td>
<td>CpG methylation</td>
<td>FCTX</td>
<td>2291</td>
<td>HLA-DRA</td>
<td>Parkinson</td>
</tr>
<tr>
<td>rs2301436</td>
<td>6</td>
<td>167437988</td>
<td>C.T</td>
<td>0.4308</td>
<td>0.8426</td>
<td>--0.35</td>
<td>0.081</td>
<td>1.05E-05</td>
<td>ILMN_1671659</td>
<td>mRNA expression</td>
<td>FCTX</td>
<td>94917</td>
<td>RNASET2</td>
<td>Parkinson</td>
</tr>
<tr>
<td>rs4077515</td>
<td>7</td>
<td>139266496</td>
<td>C.T</td>
<td>0.4274</td>
<td>0.9333</td>
<td>--0.904</td>
<td>0.076</td>
<td>3.13E-33</td>
<td>ILMN_1811301</td>
<td>mRNA expression</td>
<td>FCTX</td>
<td>56817</td>
<td>INPP5E</td>
<td>Parkinson</td>
</tr>
<tr>
<td>rs7914558</td>
<td>10</td>
<td>104775908</td>
<td>G.A</td>
<td>0.3991</td>
<td>0.9932</td>
<td>--0.696</td>
<td>0.086</td>
<td>2.50E-16</td>
<td>cg00035347</td>
<td>mRNA expression</td>
<td>FCTX</td>
<td>77700</td>
<td>NTSC2</td>
<td>Schizophrenia</td>
</tr>
<tr>
<td>rs2274910</td>
<td>1</td>
<td>160852046</td>
<td>C.T</td>
<td>0.2776</td>
<td>1</td>
<td>--0.744</td>
<td>0.09</td>
<td>1.03E-16</td>
<td>cg10103688</td>
<td>CpG methylation</td>
<td>CRBLM</td>
<td>19384</td>
<td>CD244</td>
<td>Crohns</td>
</tr>
<tr>
<td>rs2274910</td>
<td>1</td>
<td>160852046</td>
<td>C.T</td>
<td>0.2776</td>
<td>1</td>
<td>--0.744</td>
<td>0.09</td>
<td>1.03E-16</td>
<td>cg10103688</td>
<td>CpG methylation</td>
<td>CRBLM</td>
<td>19384</td>
<td>CD244</td>
<td>Crohns</td>
</tr>
<tr>
<td>rs2301436</td>
<td>6</td>
<td>167437988</td>
<td>C.T</td>
<td>0.4308</td>
<td>0.8426</td>
<td>--0.35</td>
<td>0.081</td>
<td>1.05E-05</td>
<td>ILMN_1671659</td>
<td>mRNA expression</td>
<td>FCTX</td>
<td>94917</td>
<td>RNASET2</td>
<td>Parkinson</td>
</tr>
<tr>
<td>rs4077515</td>
<td>7</td>
<td>139266496</td>
<td>C.T</td>
<td>0.4274</td>
<td>0.9333</td>
<td>--0.904</td>
<td>0.076</td>
<td>3.13E-33</td>
<td>ILMN_1811301</td>
<td>mRNA expression</td>
<td>FCTX</td>
<td>56817</td>
<td>INPP5E</td>
<td>Parkinson</td>
</tr>
<tr>
<td>rs7914558</td>
<td>10</td>
<td>104775908</td>
<td>G.A</td>
<td>0.3991</td>
<td>0.9932</td>
<td>--0.696</td>
<td>0.086</td>
<td>2.50E-16</td>
<td>cg00035347</td>
<td>mRNA expression</td>
<td>FCTX</td>
<td>77700</td>
<td>NTSC2</td>
<td>Schizophrenia</td>
</tr>
<tr>
<td>rs2274910</td>
<td>1</td>
<td>160852046</td>
<td>C.T</td>
<td>0.2776</td>
<td>1</td>
<td>--0.744</td>
<td>0.09</td>
<td>1.03E-16</td>
<td>cg10103688</td>
<td>CpG methylation</td>
<td>CRBLM</td>
<td>19384</td>
<td>CD244</td>
<td>Crohns</td>
</tr>
</tbody>
</table>

The table shows only significantly associated SNP-probe pairs after Bonferroni correction for multiple testing. Abbreviations include CRBLM for cerebellum, FCTX for frontal cortex and bp for base pair.
associations (OR \( \sim 1.05, \alpha < 0.05 \)). On the other hand, this method cannot definitively show a true negative effect for the other 16 intermediate risk factors investigated in this manuscript (particularly those with robust epidemiological associations such as smoking and caffeine intake) as the genetic contributions of known associated SNPs may be so small, and then further diluted in their biological relationship to PD risk, that these effects may be of virtually undetectable magnitude at this current period in genetic analyses.

**MATERIALS AND METHODS**

**Data mining of PD-related traits from GWAS**

The entire NHGRI GWAS catalog was downloaded on August 15, 2012. Phenotypes for each GWAS were indexed describing the diseases and quantitative traits associated with these studies. Based on a recently published systematic review of PD-related factors and consultation, we assembled a list of possible comorbidities of interest from the GWAS catalog using the disease/trait index (Supplementary Material, Table S1). From these indexed disease/trait descriptions, we extracted all keywords described in Supplementary Material, Table S1 by text mining to identify studies of relevant phenotypes for this analysis.

To extract relevant SNPs from only high-quality studies, a series of filters were used for SNP inclusion in the profiles based on data from the GWAS catalog. Minimum sample sizes for included GWAS SNPs had to be at least 1000 cases and 1000 controls for binary phenotypes in both discovery and replication analyses, and at least 1000 samples for continuous phenotypes. In addition, since all PD GWAS samples were of European ancestry, these sample size filters were based on European ancestry participants within the reported GWAS only. These SNPs must also have achieved a discovery \( P \)-value of \( \leq 5 \times 10^{-8} \) as reported in the GWAS catalog. The contributing GWAS study must also have made data available regarding allelic direction of effect for the most significant SNP per locus.

Once all high-quality studies and their reported SNPs were extracted, additional quality control was necessary prior to constructing phenotype-specific risk scores. For all GWAS SNPs associated with a specific phenotype of interest, duplicate SNPs were excluded, and SNPs within 250 kb of another SNP associated with the same phenotype were excluded if the \( r^2 \) between the two SNPs was \( >0.5 \). For SNPs in linkage disequilibrium related to the same phenotype, the more significant SNP based on discovery phase \( P \)-value was kept for construction of the risk profile scores. \( r^2 \) estimates of linkage disequilibrium were based on European ancestry samples from the most recent 1000 Genomes Project data freeze (Phase 1 alpha, version 3 available from [1]). In addition, all SNPs had to be successfully imputed in the IPDGC cohorts participating in this analysis, see below for details.

**IPDGC datasets**

Genotyping data from five IPDGC cohorts with genome-wide genotyping were extracted for use in this study. These cohorts have been described in Table 1, and in greater detail in previous publications ([49,70]). In brief, standard genome-wide association quality control was used including inclusion criteria such as:

- minimum 95% call rate per sample
- Hardy–Weinberg equilibrium \( P \)-values \( >1 \times 10^{-6} \), minor allele frequency \( >1\% \), missingness per SNP \( <5\% \).

**Risk profile construction**

For each of the 18 phenotypes of interest with high-quality SNPs available, risk profiles were constructed. This was accomplished by summing all imputed allele dosages from extracted SNPs for each phenotype per cohort. The allelic dosages were quantified as 0–2 dosages for each SNP relating to the specific allele that was associated in previous reports with either a risk increase for a disease phenotype or an increase in the level of a continuous phenotype. All risk profiles were relatively normally distributed and were then \( Z \) transformed so that effect estimates would be easily comparable. \( Z \) transformation was undertaken using the standard formula where individual profile scores were subtracted by the mean of the population for that score and then divided by their standard deviation.

**Analyses of risk profiles**

For each of the 18 profiles calculated within each of the contributing cohorts, logistic regression was used to generate summary statistics, using the profile scores as the independent variable and adjusting for age (at onset in cases and exam in controls), sex and principal components 1 and 2 derived from genotyped SNPs. The use of principal components based on an LD pruned SNP set in each cohort as a covariate allows for population substructure to be accounted for in the regression models. Summary statistics for each cohort were meta-analyzed to generate aggregate effect estimates for all profiles using random effects meta-analyses. For PD, schizophrenia and Crohn’s disease related SNPs, single SNP analyses were also performed using identical statistical methods as for the risk profile-based analyses to facilitate an in-depth examination of the individual SNPs comprising these three scores.
Expression and methylation quantitative trait analyses

Data for this aspect of analyses were made possible through collaborative efforts of the North American and United Kingdom Brain Expression Consortia (83–85). Frozen frontal cortex and cerebellar samples were obtained from >399 self-reported European ancestry samples without determinable neuropathological evidence of disease. Genomic DNA was extracted with phenol–chloroform. Bisulfite converted DNA and assayed at >27,000 sites on the Illumina Infinium HumanMethylation27 BeadChips. MRNA expression levels were assayed using Illumina HumanHT-12 v3 Expression BeadChips. In brief, individual probes were excluded from analyses if the P-value for detection was >0.01 or there was <95% completeness of data per probe, and samples were excluded if <95% of probes were detected. Probes were also removed if an analyzed SNP was within the probe or the probe mapped ambiguously to multiple locations in the genome. Expression data were cubic spline normalized and log 2-transformed prior to analyses.

Each tissue sample was genotyped using the Illumina Human-Hap550 v3, Human610-Quad v1 or Human660W-Quad v1 Infinium BeadChips, shared probes were extracted prior to QC and imputation. Standard GWAS quality control was undertaken with inclusion criteria such as: minimum call rate 95% for both participants and SNPs, minor allele frequency (MAF) >0.01, HWE >1E-7, no first-degree relatives in the sample collection (identity by descent score <0.125 in PLINK) and European ancestry confirmed by multidimensional scaling analyses.

Data were imputed using MiniMac (http://genome.sph.umich.edu/wiki/Minimac) to the most recent data freeze of 1000 Genomes haplotypes (http://www.sph.umich.edu/csg/abecasis/MaCH/download/1000G.2012-03-14.html) using default settings. All imputed SNPs were filtered for a minimum imputation quality of 0.30. After quality control, data were available for >10 million SNPs, with expression data on 399 samples (9814 probes from the frontal cortex and 9587 probes in cerebellum) and methylation data on 292 samples (27465 CpG sites in the frontal cortex tissue samples and 27419 CpG sites in the cerebellum).

Linear regression models were utilized to estimate associations between allele dosages of per SNP and gene expression or methylation levels adjusted for covariates of gender, age at death, the first two component vectors from multidimensional scaling, postmortem interval, brain bank and batch in which preparation or hybridization were performed, using MACH2QTLv1.11 (http://www.sph.umich.edu/csg/abecasis/MaCH/download/). Analyses were carried out separately for each brain region and each array type. Only probes within ±1 mb of SNPs of interest in this study were analyzed to test only cis associations. From these analysis results, data were mined for SNPs comprising the Crohn’s disease, PD and schizophrenia risk profiles. Multiple test correction was based on simple Bonferroni correction stratified by brain region and assay type.

ACKNOWLEDGEMENTS

We thank and acknowledge all who made this research possible, please see Supplementary Material, Text S1 for full consortia membership. This study utilized the high-performance computational capabilities of the Biowulf Linux cluster at the National Institutes of Health, Bethesda, MD (http://biowulf.nih.gov), and DNA panels, samples and clinical data from the National Institute of Neurological Disorders and Stroke Human Genetics Resource Center DNA and Cell Line Repository. People who contributed samples are acknowledged in descriptions of every panel on the repository website. We thank the French Parkinson’s Disease Genetics Study Group: Y. Agid, M. Anheim, A.-M. Bonnet, M. Borg, A. Brice, E. Broussolle, J.-C. Corvol, P. Damier, A. Destée, A. Dürr, F. Durif, S. Klebe, E. Lohmann, M. Martinez, P. Pollak, O. Rascol, F. Tison, C. Tranchant, M. Véron, F. Viallet and M. Vialilh. We also thank the members of the French 3C Consortium: A. Alpérovitch, C. Berr, C. Tzourio and P. Amouyel for allowing us to use part of the 3C cohort, and D. Zelenika for support in generating the genome-wide molecular data. We thank P. Tienari (Molecular Neurology Programme, Biomedical, University of Helsinki), T. Peura (Department of Neurology, Helsinki University Central Hospital), L. Myllykangas (Folkhalsan Institute of Genetics and Department of Pathology, University of Helsinki) and R. Sulkava (Department of Public Health and General Practice Division of Geriatrics, University of Eastern Finland) for the Finnish controls (Vantaa85+ GWAS data).

Conflict of Interest statement. None declared.

FUNDING

For details on funding, refer Supplementary Material, Text S1.

REFERENCES


